Skin cancer vaccine BLA submitted by...?

根據「Skin cancer vaccine BLA submitted by...?」的最新預測市場資料，交易者已形成強烈共識。

目前，June 30, 2027? 以壓倒性的 75.5% 獲勝機率主導市場；March 31, 2027 以 53.5% 位居第二。該市場的下注量已達 $90.7K，反映出市場的高度關注。

為了更好地評估各潛在結果的位置，可依據隱含機率與合約定價將市場劃分為三個明顯的交易梯隊：

🥇 第一梯隊：絕對領跑者

• June 30, 2027? (75.5%)：June 30, 2027? 目前擁有最高機率，深受訂單簿青睞。看好該結果的交易者面對的「Buy Yes」合約價為 76¢，顯示出市場的高度確信。僅該合約就已產生 $71.6K 的成交量。

🥈 第二梯隊：主要挑戰者

• March 31, 2027 (53.5%)：作為最可行的替代選項，March 31, 2027 保持著 53.5% 的成真機率，其「Buy Yes」份額目前成交價為 54¢。

This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No".

Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.

A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication.

A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof.

The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify.

If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed.

The primary resolution source for this market will be official communications from the company submitting the BLA, the FDA, or authorized representatives thereof; however, a consensus of credible reporting may also be used.

人群共識與投機成交塑造了更宏觀的預測市場，而我們的量化演算法提供了資料驅動的反向視角。透過分析基本面訊號、底層趨勢與歷史分布，我們的 AI 估值模型為每個結果獨立測算出一個「公允價值」機率。

將該公允價值與當前交易價值對比，可揭示出重大背離——即期望值（EV）差。正 EV 差代表統計上被低估的結果，而負 EV 差則提示市場可能存在反應過度。

頂級 AI Alpha 與錯誤定價套利機會

根據最新一輪資料模型測算，以下幾個關鍵合約存在顯著偏離：

• 最被高估的結果：March 31, 2027 當前交易價為 53.5%，但我們的 AI 測算其公允價值僅為 50%，形成 -3.6% 的較大負 EV 差，表明人群可能過度炒作該結果、把溢價推得過高。
• 最佳價值標的（最高 EV）：我們的模型將 June 30, 2027? 識別為盤面上最具價值的機會。市場僅給予其 75.5% 的交易機率，而我們 AI 的公允價值評估為 83.6%——形成可觀的 +8.1% EV 差。